COMMUNIQUÉS West-GlobeNewswire

Bexorg Expands Leadership Team with Appointments of Bruce Car, Ph.D., as Chief Scientific Officer and Michael Fenn, Ph.D., as Chief Business Officer
13/07/2026
- Dr. Car brings more than 30 years of drug discovery experience to lead Bexorg's next phase of clinical translation; Dr. Fenn joins Bexorg to lead business development, asset strategy, and corporate development - [...]
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
13/07/2026
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and [...]
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
13/07/2026
IP portfolio reflects Autonomix’s neural sensing leadership in multi-billion-dollar denervation market Technical highlights on newly issued patent include real-time nerve monitoring and diagnostic evaluation THE [...]
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
13/07/2026
Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using [...]
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE [...]
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
13/07/2026
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, [...]
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
13/07/2026
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- [...]
VitalHub Announces Acquisition of Buddy Healthcare
13/07/2026
TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (“VitalHub” or the “Company”) announced today that it has acquired Buddy Healthcare Ltd Oy (“Buddy Healthcare”), a care coordination [...]
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
13/07/2026
Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark [...]
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
13/07/2026
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial payer agreements [...]
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
13/07/2026
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization REHOVOT, Israel and HOBOKEN, N.J., July 13, [...]
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
13/07/2026
SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative [...]
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
13/07/2026
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months The most common adverse events reported were consistent [...]
New Phase 1 Data Show VNA-318 Mechanism of Action Translates to Humans, Supporting Potential to Address Medical Needs of People with Neurodegenerative Diseases
13/07/2026
Pharmacodynamic effects in the human brain and energy metabolism biomarker data presented at AAIC support further clinical development of VNA-318 in Alzheimer’s disease LAUSANNE, Switzerland, July 13, 2026 – Vandria, a [...]
Bavarian Nordic – Completion of Share Buy-Back Program
13/07/2026
COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on June 2, 2026, has now been completed, reaching an aggregate amount of [...]
Oxford Brain Diagnostics Advances Vision for Measuring Brain Health and Neurodegenerative Disease with Five New Studies at AAIC 2026
13/07/2026
New findings demonstrate the potential of OBD's MRI-based Cortical Disarray Measurement (CDM®) technology to support patient identification, disease characterization, treatment monitoring, and therapeutic development [...]
Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
13/07/2026
National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. Resulting dataset will be [...]
SCENESSE® approved for EPP in Canada
13/07/2026
Health Canada NOC enables treatment for porphyria, metabolic disorder MELBOURNE, Australia, July 13, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s novel drug SCENESSE® (afamelanotide) has been granted a Notice of Compliance (NOC [...]
Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus
13/07/2026
Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the partnership to [...]

Pages